ARS-853 is a selective, covalent KRASG12C inhibitor with an IC50 of 2.5 uM.
CAS：1629268-00-3
分子式：C22H29ClN4O3
分子量：432.94
纯度：98%
存储：Store at -20°C

Background:

ARS-853 is a selective, covalent KRASG12C inhibitor with an IC50 of 2.5 uM.

ARS853 is designed to bind KRASG12C with high affinity. Treatment of KRASG12C-mutant lung cancer cells with ARS853 reduces the level of GTP-bound KRAS by more than 95% (10 uM). ARS853 inhibits proliferation with an inhibitory concentration 50% (IC50) of 2.5 uM, which is similar to its IC50 for target inhibition. ARS853 (10 uM) inhibits effector signaling and cell proliferation to varying degrees in six KRASG12C mutant lung cancer cell lines, but not in non-KRASG12C models. Similarly, it completely suppresses the effects of exogenous KRASG12C expression on KRAS-GTP levels, KRAS-BRAF interaction, and ERK signaling. ARS-853 treatment also induces apoptosis in four KRASG12C mutant cell lines. ARS853 selectively reduces KRAS-GTP levels and RAS-effector signaling in KRASG12C-mutant cells, while inhibiting their proliferation and inducing cell death[1]. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation[2].

参考文献:
[1]. Lito P, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016 Feb 5;351(6273):604-8.
[2]. Patricelli MP, et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016 Mar;6(3):316-29.